Collaboration Agreements

Collaboration agreements are the tangible results of WIPO Re:Search's work. On behalf of WIPO Re:Search, BIO Ventures for Global Health (BVGH), helps our members to find other members with whom their wants/needs coincide. BVGH then assists members to conclude a research collaboration agreement.

Collaborations cover a range of areas that include the sharing of data and services (such as access to company research facilities, screening of compounds, hosting of scientists) as well as other forms of expertise. The 10 most recent collaboration agreements are presented below.

Need more comprehensive information?

The full list of collaboration agreements is available in PDF format.

Year Provider User Research description
2017 Eisai UCSD, NEU Eisai will provide UCSD and NEU researchers with a targeted set of inhibitors and their structures to test against Leishmania spp. and T. cruzi.
2017 GSK UC Berkeley GSK will provide a UC Berkeley researcher with a set of small molecules that were previously demonstrated to have promising activity against M. tuberculosis-infected macrophages in vitro. The UC Berkeley researcher will use his novel assays to assess whether the molecules’ anti-tubercular activities are due to activation of the host macrophages’ autophagy pathway.
2017 Janssen R&D NIH Janssen Research & Development will provide National Institutes of Health researchers with its Jump-stARter library to screen against Mycobacterium tuberculosis in vitro under conditions that mimic important aspects of human pathogenesis.
2017 Janssen R&D U Toronto Janssen Research & Development will provide a University of Toronto researcher with its Jump-stARter library. The researcher will screen the library against C. elegans to identify inhibitors of a unique metabolic pathway found in parasitic worms.
2017 Janssen R&D WUSTL Janssen Research & Development will provide a Washington University in St. Louis (WUSTL) researcher with its Jump-stARter library to screen against a Mycobacterium tuberculosis enzyme demonstrated to be essential for the growth and virulence of the bacterium.
2017 Merck KGaA, Darmstadt, Germany UCSD Merck KGaA, Darmstadt, Germany will provide a University of California, San Diego (UCSD) investigator with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. The UCSD investigator will screen these inhibitors for activity against the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis.
2017 NIPD CPC A National Institute of Parasitic Diseases, China CDC (NIPD) researcher will sequence the K13 gene of Plasmodium falciparum parasites found within malaria patient blood samples obtained by researchers at the Centre Pasteur du Cameroun (CPC). The researchers seek to assess the development of artemisinin resistance in Plasmodium parasites circulating in Cameroon, and to compare parasite genotypes with the patients’ responses to treatment – specifically parasite clearance.
2017 Takeda NIAID Takeda Pharmaceutical Company Limited and the National Institute of Allergy and Infectious Diseases (NIAID) will examine the feasibility of using Takeda’s microneedle patch technology to administer a protein antigen-based, transmission-blocking malaria vaccine developed by the NIAID’s Laboratory of Malaria Immunology and Vaccinology (LMIV). Under this agreement, Takeda and LMIV will confirm the compatibility of the vaccine antigen and microneedle patch polymer. The NIAID scientists will subsequently evaluate the immunogenicity of the patch-administered vaccine in vivo.
2017 Takeda UCSF Takeda will provide a UCSF researcher with a set of preclinical/clinical-stage compounds to screen against B. pahangi.
2017 USF U Yaoundé I A USF natural products chemist will attempt to isolate, characterize, and elucidate the structures of several fractions and pure compounds from Cameroonian fungi and medicinal plants. A University of Yaoundé I researcher previously demonstrated the promising effect of these products against M. ulcerans, Leishmania spp., T. brucei, and S. mansoni. These products’ characterizations are the first step towards their development as drugs.